The estimated Net Worth of Mark Chin is at least $6.22 Million dollars as of 15 June 2023. Mr. Chin owns over 15,853 units of Harpoon Therapeutics stock worth over $421,221 and over the last 6 years he sold HARP stock worth over $5,648,687. In addition, he makes $153,229 as Independent Director at Harpoon Therapeutics.
Mark has made over 9 trades of the Harpoon Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 15,853 units of HARP stock worth $364,778 on 15 June 2023.
The largest trade he's ever made was buying 1,333,333 units of Harpoon Therapeutics stock on 16 July 2021 worth over $7,999,998. On average, Mark trades about 76,485 units every 61 days since 2018. As of 15 June 2023 he still owns at least 18,306 units of Harpoon Therapeutics stock.
You can see the complete history of Mr. Chin stock trades at the bottom of the page.
Mark Chin serves as Independent Director of the Company. Mr. Chin currently serves as a member of the Board of Directors of public companies Imara Inc. (Nasdaq: IMRA) and Iterum Therapeutics (Nasdaq: ITRM). Mr. Chin served as an investment director at Arix Bioscience, a biotechnology-focused venture capital firm, from July 2016 to April 2020. Prior to Arix Bioscience, he was a principal at Longitude Capital, a healthcare venture capital firm, from January 2012 to August 2018, where he focused on investments in both private and public biotechnology and medical technology companies. Prior to Longitude Capital, Mr. Chin was a consultant at the Boston Consulting Group, a global management consulting firm, from January 2011 to January 2012, where he managed strategy and corporate development projects for pharmaceutical and biotechnology companies, and prior to Boston Consulting Group, he worked in corporate development at Gilead Sciences, a biotechnology company, and in market planning at Genentech, a biotechnology company. Mr. Chin holds a B.S. in Management Science from the University of California at San Diego, an M.S. in Biotechnology from the University of Pennsylvania and an M.B.A. from The Wharton School at the University of Pennsylvania. Our Board believes that Mr. Chin’s expertise and experience in the life sciences industry, experience as a director of other companies in our industry and his educational background provide him with the qualifications and skills to serve on our Board.
As the Independent Director of Harpoon Therapeutics, the total compensation of Mark Chin at Harpoon Therapeutics is $153,229. There are 6 executives at Harpoon Therapeutics getting paid more, with Gerald McMahon having the highest compensation of $1,793,260.
Mark Chin is 38, he's been the Independent Director of Harpoon Therapeutics since 2017. There are 14 older and no younger executives at Harpoon Therapeutics. The oldest executive at Harpoon Therapeutics, Inc. is Gerald McMahon, 65, who is the President, Chief Executive Officer, Director.
Mark's mailing address filed with the SEC is C/O HARPOON THERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt und Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics executives and other stock owners filed with the SEC include: